Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
meeting tags : Fda save search
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Published: 2024-04-11 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 1.85%
H: 0.0%
C: 0.0%
biotech fda breast cancer for meeting trial submission
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
Published: 2024-04-03 (Crawled : 12:00) - globenewswire.com
LIPO | $0.706 -5.74% -6.09% 19K
|
|
| O: 1.43%
H: 0.0%
C: -2.82%
lp-10 fda pharmaceuticals meeting
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
Published: 2024-04-03 (Crawled : 12:00) - globenewswire.com
IKT | News | $2.13 0.19% 28K
|
Health Technology
|
| O: -0.93%
H: 7.04%
C: 0.94%
fda meeting hypertension therapeutics
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
Published: 2024-03-19 (Crawled : 21:00) - globenewswire.com
AEON | $6.54 -3.68% 0.0% 41K
|
|
| O: -4.03%
H: 7.45%
C: -8.9%
abp-450 fda update treatment biopharma meeting migraine
Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting
Published: 2024-03-14 (Crawled : 21:00) - globenewswire.com
AQST | $4.505 14.92% 12.99% 5.8M
|
Health Technology
|
| O: 3.05%
H: 14.23%
C: 12.57%
fda update meeting therapeutics study
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
Published: 2024-03-14 (Crawled : 12:30) - biospace.com/
CYBN | News | $0.3699 -1.47% 1.05% 1.7M
|
n/a
|
| O: 7.14%
H: 5.53%
C: -4.67%
cyb003 fda positive meeting program design
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
Published: 2024-02-28 (Crawled : 21:00) - globenewswire.com
IKT | News | $2.13 0.19% 28K
|
Health Technology
|
| O: 4.5%
H: 1.29%
C: -6.9%
fda meeting therapeutics
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
Published: 2024-02-27 (Crawled : 13:30) - globenewswire.com
CAPR | $5.055 -8.92% -9.79% 940K
|
Health Technology
|
| O: 2.53%
H: 13.6%
C: 6.9%
cap-1002 fda meeting commercial therapeutics duchenne
Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development
Published: 2024-02-27 (Crawled : 12:00) - prnewswire.com
ACXP | $2.11 17.22% 14.69% 140K
|
Professional, Scientific, and T...
|
| O: 1.54%
H: 1.52%
C: -5.15%
fda granted ibezapolstat infection designation meeting
Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection
Published: 2024-02-21 (Crawled : 15:30) - biospace.com/
ENSC | $0.5805 -7.83% -8.49% 90K
|
Health Technology
|
| O: 1.07%
H: 2.5%
C: -3.12%
pf614 fda opioid meeting
Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation
Published: 2024-02-16 (Crawled : 12:30) - globenewswire.com
IXHL | $2.42 0.0% 9.5K
|
Manufacturing
|
| O: -6.59%
H: 15.33%
C: 13.14%
fda solution meeting
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
Published: 2024-02-07 (Crawled : 13:00) - globenewswire.com
IKT | News | $2.13 0.19% 28K
|
Health Technology
|
| O: -9.06%
H: 5.35%
C: 0.37%
fda approval blood meeting gastrointestinal therapeutics
Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain
Published: 2024-01-31 (Crawled : 15:00) - biospace.com/
ENSC | $0.5805 -7.83% -8.49% 90K
|
Health Technology
|
| O: 29.51%
H: 4.55%
C: -13.14%
pf614 fda positive treat meeting
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
Published: 2024-01-31 (Crawled : 13:00) - globenewswire.com
DARE | $0.299 5.77% 5.45% 970K
|
Health Technology
|
| O: -2.16%
H: 8.61%
C: 1.06%
fda company positive bioscience meeting
Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch
Published: 2024-01-24 (Crawled : 15:30) - biospace.com/
PTPI | $0.69 0.0% 230K
|
|
| O: -2.4%
H: 4.92%
C: -5.74%
fda review pharmaceuticals
60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting
Published: 2024-01-22 (Crawled : 13:00) - globenewswire.com
SXTP | $0.245 -2.7% -2.78% 44K
|
n/a
|
| O: 5.11%
H: 35.11%
C: 14.13%
fda pharma meeting study
Clearmind Medicine Completed Type A Meeting with the FDA
Published: 2024-01-10 (Crawled : 12:30) - globenewswire.com
CMND | $1.2 0.84% 0.83% 35K
|
n/a
|
| O: 69.57%
H: 1.99%
C: -16.52%
fda meeting
Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Published: 2024-01-05 (Crawled : 14:30) - biospace.com/
COYA | News | $8.53 3.52% 3.4% 30K
|
|
| O: 1.94%
H: 2.79%
C: 0.0%
fda sclerosis treatment therapeutics
Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts
Published: 2024-01-04 (Crawled : 12:30) - globenewswire.com
VRCA | $6.91 -2.13% -2.17% 200K
|
Health Technology
|
| O: -0.44%
H: 2.51%
C: -0.89%
fda treatment pharmaceuticals meeting
60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024
Published: 2023-12-26 (Crawled : 13:00) - globenewswire.com
SXTP | $0.245 -2.7% -2.78% 44K
|
n/a
|
| O: 33.08%
H: 27.5%
C: -3.75%
fda pharma approval meeting study
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.